TEpiNom:一个集成人口数据的计算框架,以优先考虑plasmodium falciparum T细胞表位
Alexander J Laurenson1, Brian G Pierce2, Shannon Takala-Harrison3
1Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA; Molecular Microbiology and Immunology Program, Graduate Program in Life Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Vaccine
|March 3, 2026
概括
由于寄生虫的多样性,开发新的疟疾疫苗是很困难的. 我们创建了一个计算工具,T细胞表位表征 (TEpiNom),以找到保存的T细胞表位表征,以获得更好的疫苗候选者.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 计算生物学 计算生物学
背景情况:
- 开发有效的疟疾疫苗受到Plasmodium falciparum的遗传多样性和人类白细胞抗原 (HLA) 变异的阻碍.
- 像RTS,S这样的现有疟疾疫苗提供了有限的,异位基因特定的保护,免疫力下降,需要改进的策略.
- 疫苗的抗原选择因HLA多态性而复杂,影响免疫反应的广度和有效性.
研究的目的:
- 开发一个计算框架,T细胞表皮图命名 (TEpiNom),用于为疟疾疫苗开发优先考虑保存的T细胞表皮图.
- 整合Plasmodium falciparum序列多样性,预测的T细胞表皮质与HLA结合,以及撒哈拉以南非洲的HLA等位基因频率.
- 在所有寄生虫生命阶段识别保存的T细胞表位和表位密集区域,用于潜在的疫苗候选人.
主要方法:
- 分析了42种P. falciparum疫苗候选蛋白质,从18个非洲国家产生共识序列.
- 从24个撒哈拉以南地区的人口中结合了HLA等位基频率和使用NetMHCpan-4.1和NetMHCIIpan-4.1.1预测的T细胞表位.
- 在TEpiNom中应用了整数线性编程,以基于保护,HLA结合和覆盖率来优先考虑表位,最大限度地减少冗余.
主要成果:
- 确定了2265个MHC I和1992年的MHC II保存表位体,跨越了前红细胞,红细胞和性阶段.
- 优先考虑的MHC I表位实现了预测的100%的MHC I介位覆盖率;MHC II表位为特定的寄生虫阶段提供了100%的覆盖率.
- 在所有寄生虫生命阶段发现了短,保存,表位密集的区域,具有高的HLA诱导潜力.
结论:
- TEpiNom系统地优先考虑T细胞表位和表位密集区域,简化临床前疟疾疫苗开发.
- 该框架将计算预测改进为更有效的疟疾疫苗的实验可行的候选人.
- TEpiNom可适应开发针对其他具有显著抗原多样性和免疫逃避策略的病原体的疫苗.
更多相关视频
相关概念视频
Statistical Software for Data Analysis and Clinical Trials
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...


